CA Patent

CA1215976A — New process for the synthesis of imidazo rifamycins

Assigned to Alfa Farmaceutici SpA · Expires 1986-12-30 · 39y expired

What this patent protects

ABSTRACT A process for the synthesis of imidazo rifamycins of for-mula wherein R is hydrogen or acetyl, R1 and R2 independently re-present hydrogen, (C1-4)-alkyl, benzyloxy, mono- or di-(C1-3)--alkylamino-(C1-4)-alkyl, (C1-3)-alkoxy-(C1-4)-alkyl, hydroxy--(C1-4)-alkyl, …

USPTO Abstract

ABSTRACT A process for the synthesis of imidazo rifamycins of for-mula wherein R is hydrogen or acetyl, R1 and R2 independently re-present hydrogen, (C1-4)-alkyl, benzyloxy, mono- or di-(C1-3)--alkylamino-(C1-4)-alkyl, (C1-3)-alkoxy-(C1-4)-alkyl, hydroxy--(C1-4)-alkyl, cyano, halogen, nitro, mercapto, (C1-4)-alkylthio, phenylthio, carbamoyl, mono- or di-(C1-4)-alkyl-carbamoyl, or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by 1 or 2 methyl or ethyl groups. The process comprises reacting the rifamycin S of formula II with a 2-aminopyridine of formula III wherein R1 and R2 have the above seen meanings.

Drugs covered by this patent

Patent Metadata

Patent number
CA1215976A
Jurisdiction
CA
Classification
—
Expires
1986-12-30
Drug substance claim
No
Drug product claim
No
Assignee
Alfa Farmaceutici SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.